Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 3Thoracic 1Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Melanoma 2653Lymphoma, T-Cell, Cutaneous 479Skin Neoplasms 408Carcinoma, Non-Small-Cell Lung 377Mycosis Fungoides 330Neoplasms 319Keratosis, Actinic 300Sezary Syndrome 294Breast Neoplasms 285Neoplasm Metastasis 284Carcinoma, Renal Cell 280Lymphoma, Non-Hodgkin 276Lymphoma 264Carcinoma, Basal Cell 263Lymphoma, Large B-Cell, Diffuse 261Leukemia, Lymphocytic, Chronic, B-Cell 261Lymphoma, Follicular 259Hodgkin Disease 247Lymphoma, Mantle-Cell 245Lymphoma, B-Cell, Marginal Zone 245Precursor Cell Lymphoblastic Leukemia-Lymphoma 243Uveal Melanoma 234Burkitt Lymphoma 233Lymphoma, Large-Cell, Immunoblastic 223Colorectal Neoplasms 196Lymphoma, Large-Cell, Anaplastic 190Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 186Ovarian Neoplasms 181Squamous Cell Carcinoma of Head and Neck 180Lung Neoplasms 179

Interventions

ripretinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Mast Cell Activation Disorders × Dermatologic × Clear all
NCT02571036 2023-12-13

A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies

Deciphera Pharmaceuticals, LLC

Phase 1 Completed
282 enrolled
CNSDermatologicGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmSarcomaThoracic

Mast Cell Activation Disorders, Carcinoma, Non-Small-Cell Lung, Glioma, Leukemia, Mast-Cell, Melanoma, Neoplasms, Germ Cell and Embryonal, Penile Neoplasms, Sarcoma, Mastocytosis, Systemic, Gastrointestinal Stromal Tumors, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡